EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Clinical study on adenocarcinoma of the prostate


Acta Urologica Japonica 39(10): 913-917
Clinical study on adenocarcinoma of the prostate
A clinical study was performed on 75 patients with untreated prostatic cancer who had been hospitalized over a 5-year period. The age range was 52 to 90 years (median age: 72.3 years). The main complaint was dysuria in 73% of the cases. Thirty-two (43%) patients were smokers, and complications included bladder cancer in two and rectal cancer in one. The stages were T1 in 18 cases, T2 in 10, T3 in 29 and T4 in 18, 28 cases were G1, 29 were G2, 11 were G3 and seven were G4. Among the tumor markers, PA sensitivity was the highest, but all markers showed high sensitivities in the T3 and T4 cases. Endocrinological treatment was performed on 74 patients. Survival rates showed significant differences only for the T and M classifications; no significant differences in survival rates according to the G classification, age of the patient or tumor markers were observed. Radiotherapy was suggested to be related to improvements in the prognosis only in patients with histological grading of G2.


Accession: 008328730



Related references

A Clinical and Immunohistochemical Study of Papillary Adenocarcinoma of the Prostate. Prostate. 26(1): 23-27, 1995

A clinical and immunohistochemical study of papillary adenocarcinoma of the prostate. Prostate 26(1): 23-27, 1995

Immunohistochemical study of the prostatic tissues with monoclonal antibody against gamma-seminoprotein. Analyses of benign prostatic hyperplasia, metastatic foci from adenocarcinoma of the prostate and malignant neoplasms other than adenocarcinoma of the prostate. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 84(3): 527-534, 1993

Percutaneous transperineal cryosurgical ablation of the prostate for the primary treatment of clinical stage C adenocarcinoma of the prostate. Urology 44(2): 170-174, 1994

Cryosurgical ablation of the prostate in patients with clinical stage A, B and C adenocarcinoma of the prostate Outcomes of PSA and biopsy at 3, 12 and 24 months. Journal Of Urology. 151(5 Suppl.): 375a, 1994

Phase II trial of edatrexate in patients with adenocarcinoma of prostate using prostate specific antigen as the clinical endpoint. Proceedings of the American Association for Cancer Research Annual Meeting 34(0): 203, 1993

Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. Journal of Cellular Biochemistry 112(1): 341-353, 2011

Increased expression of MUC18 correlates with the metastatic progression of prostate adenocarcinoma in the transgenic adenocarcinoma mouse prostate model. Proceedings of the American Association for Cancer Research Annual Meeting 44: 58, July, 2003

Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles a case report with immunocytochemical analysis and review of the literature. Cancer 66(5): 998-1001, 1990

Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature. Cancer 66(5): 998-1001, 1990